1. Scrip
  2. >>New Products

BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

Opdivo, Eliquis Rise From Year-Ago Quarter, But Down From Q2

 
• By Mandy Jackson

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Business investment growth concept with abstract arrows on building
Total third quarter revenue of $11.6bn was up 10% from Q3 2020 • Source: Alamy

Bristol Myers Squibb Company reported $11.6bn in third quarter revenue that exceeded analyst consensus on 27 October, driven in part by newer product sales, which more than doubled from Q1 to Q3. The company, under pressure to produce significant revenue growth before mega-blockbuster Revlimid (lenalidomide) begins to face loss of exclusivity next year, also largely has seen success in its research and development pipeline since acquiring Celgene Corporation at the end of 2019 despite some initial stumbles.

Volume-limited Revlimid generics will begin to launch in the US in 2022 along with generics in some ex-US markets. The Celgene acquisition brought the multiple myeloma drug – now...

Q3 New Product Sales

  • Reblozyl, $160m in Q3, up 67% from $96m in Q3 2020

  • Inrebic, $22m, up 69% year-over-year from $13m

  • Onureg, $21m versus $3m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.